Clinical Trial Update: DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY [Phase 3]

View source ↗

Summary

Phase 3 trial update on DEF-314 showing better accuracy in ejection fraction assessment with DEFINITY.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Disease

Drugs mentioned

• DEF-314
• DEFINITY (perflutren lipid microspheres)

Snippet

Sponsor: Lantheus Medical Imaging | Conditions: Cardiac Disease | Phase 3 | Status: COMPLETED | Results posted: 2020-12-17